Aurinia Q2 revenue up 22% to $70M; net income $21.5M; raises FY2025 guidance

Aurinia Pharmaceuticals Inc.

2025-Q2 EPS reported $0.32 vs consensus $0.15 ▲ beat (+113.9%)

Total revenue $70.0M (+22% YoY); net product sales $66.6M (+21%); net income $21.5M vs $0.7M in Q2 2024.
H1 2025 revenue $132.5M (+23%); net income $44.9M vs loss of $10.0M; operating cash flow $45.5M.
FY2025 total revenue guidance raised to $260-270M (from $250-260M); net product sales $250-260M.
Board approved $150M increase to share repurchase plan; $138.4M spent on 18.3M shares since Feb 2024.
Positive Phase 1 data for dual BAFF/APRIL inhibitor aritinercept; plans to start Phase 2 in 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.